Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now early-phase tilt

Eczema: early-phase trial registry

13 of 30 indexed Eczema trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #519 of 28,707 conditions by registered trial count.

30 US clinical trials · 13 currently recruiting · #519 of 28,707 conditions by registered trial count

Eczema: 30 US clinical trials tracked, 13 recruiting.

Eczema is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Seeding, running 2 of these trials.

Enrollment posture brief

Registry condition eczema

OPEN 13 | RECR 43% | LATE 6 | EARLY 11 | RANK #519 | SPON 2

Nearest open-share peer: Bronchopulmonary Dysplasia (43% recruiting · 30 trials)

AML60%Eczema (this)43%Acute Myeloid Leukemia40%Anatomic Stage IA Breast Can26.7%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Eczema

Eczema lists 13 open slots (43% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Eczema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Eczema is recruiting above its size-band peers.

    13 of 30 indexed trials (43.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Eczema trials is spread across many organizations.

    Seeding accounts for 2 of 30 trials (6.7%). 29 distinct sponsors appear on at least one study for this condition label.

  3. Typical Eczema enrolment sits around 125 participants.

    Median target enrolment is 125 among the 30 trials that report a genuine target (sentinel values excluded). 12 of those (40%) plan for fewer than 100 participants.

  4. Eczema research is mostly interventional.

    22 interventional and 8 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 29Phase 33Phase 43

Open and recent trials

30 total, page 1 of 1

RECRUITING 900 participants

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

University of California, San Diego

NCT05938478

RECRUITING 530 participants

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

National Human Genome Research Institute (NHGRI)

NCT00605878

RECRUITING NA 250 participants

Flourish: Exploring the Early Infant Gut Microbiome

Seeding

NCT07333482

RECRUITING Phase 2 220 participants

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene

NCT07037901

RECRUITING 200 participants

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

University of Pittsburgh

NCT00177268

RECRUITING Phase 2 200 participants

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Corvus Pharmaceuticals

NCT07441395

RECRUITING Phase 3 150 participants

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Pfizer

NCT06807268

RECRUITING Phase 2 130 participants

Effects of Treatments on Atopic Dermatitis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT01631617

RECRUITING Phase 1 125 participants

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Arcutis Biotherapeutics

NCT07453602

RECRUITING Phase 2 120 participants

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06096857

RECRUITING Phase 2 100 participants

A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)

Turn Therapeutics

NCT07355075

RECRUITING Phase 2 96 participants

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Aclaris Therapeutics

NCT07011706

RECRUITING 90 participants

Sodium in the Skin and Atopic Dermatitis

University of California, San Francisco

NCT06998446

ACTIVE NOT RECRUITING 505 participants

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Northwestern University

NCT01782703

ACTIVE NOT RECRUITING Phase 2 398 participants

Seal, Stopping Eczema and Allergy Study

Kari Nadeau, MD, PhD

NCT03742414

ACTIVE NOT RECRUITING Phase 3 367 participants

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT05559359

ACTIVE NOT RECRUITING NA 100 participants

Infant Restore: Efficacy of Microbiome Analysis and Education

Seeding

NCT06424691

COMPLETED Phase 3 599 participants

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Stiefel, a GSK Company

NCT00817063

COMPLETED NA 300 participants

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

University of Southern California

NCT03981926

COMPLETED Phase 2 180 participants

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

Nucryst Pharmaceuticals

NCT00076375

COMPLETED Phase 2 87 participants

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Janssen Research & Development

NCT04021862

COMPLETED NA 63 participants

Joovvin' for Your Skin Health Study

ProofPilot

NCT04471896

COMPLETED 60 participants

Oral Bacteria and Allergic Disease in Children

National Institute of Environmental Health Sciences (NIEHS)

NCT00438646

COMPLETED 59 participants

Sleep, Circadian Rhythm & Skin Health

University Hospitals Cleveland Medical Center

NCT02457000

COMPLETED Phase 4 30 participants

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Ann & Robert H Lurie Children's Hospital of Chicago

NCT04023084

COMPLETED Phase 4 30 participants

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

Frankel, Amylynne, M.D.

NCT01202149

COMPLETED 30 participants

Bone Health in Patients With Atopic Dermatitis

Mayo Clinic

NCT03800004

COMPLETED Phase 1 28 participants

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

AOBiome

NCT03775434

COMPLETED Phase 4 24 participants

Steroid-reducing Effects of Crisaborole

Johns Hopkins University

NCT03832010

COMPLETED NA 9 participants

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

Rockefeller University

NCT01149759

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 9
Phase 3 3
Phase 4 3

Named interventions

Most-linked intervention names on Eczema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
7 trials
Crisaborole Drug
2 trials
Consult Call Behavioral
2 trials
Tailored Recommendations Dietary supplement
2 trials
Bermekimab Monoclonal Antibody Drug
1 trials
Joovv Mini Device
1 trials
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device) Device
1 trials
Nanocrystalline silver cream (NPI) Drug
1 trials

US sites by state

Facility locations filed on Eczema trials. A trial with sites in several states counts in each.

California 12 trials
Florida 7 trials
Texas 6 trials
Ohio 6 trials
New York 6 trials
Illinois 5 trials
Arkansas 5 trials
South Carolina 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Eczema page

30 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 13 Eczema trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Seeding sponsors the most Eczema trials on record, review their full trial history before evaluating a specific study. See Seeding's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eczema condition card totals 30 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.